What is EndoPredict®?

The EndoPredict® (known simply as EP) adopts real-time polymerase chain reaction (RT-PCR) with the most stringent design and with greater accuracy to analyze genes associated with breast cancer in each individual patient. At the same time, EP incorporates the clinical factor of a tumor and takes both gene expression and clinical factors into account to determine whether the patient is at risk of breast cancer recurrence within 10 years. This test also provides doctors and patients with an understanding of whether chemotherapy is necessary.

Why EndoPredict® is the test of choice for you?

EndoPredict® test result will provide your individual risk of breast cancer recurrence within 10 years. It will help you and your doctor decide whether you can be safely treated with anti-hormonal therapy alone. Patients with low-risk breast cancer only need anti-hormonal therapy to effectively prevent the recurrence of breast cancer.

early-stage breast cancer patients with ER positive, HER2 negative tumor

Do all breast cancer patients need chemotherapy?

Over 65% of early-stage breast cancer patients have ER positive, HER2 negative breast cancer. EP can help you and your doctors determine the necessity of chemotherapy.

Step 1：Physician or nurse explains test procedure
Step 2：Sign consent form and provide tissue sample
Step 3：Sample delivered to laboratory
Step 4：Using newest RT-PCR technology
Step 5：The report is completed in 10 working days

*This test can only serve as a reference for professional medical personnel. Please consult your doctor regarding the clinical meaning of the results or any other medical issues.